drugset / Trial / NCT06659653
Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
NaSingle-groupOpen-labelTreatment
Summary
A Clinical Study on the Safety and Effectiveness of CD19/CD22 Chimeric Antigen Receptor T Cells in the Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
Timeline
- Start
- 2024-05-24
- Primary completion
- 2027-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRG2302 | Unknown | 500000 cells/kg | — |
| Subject | PRG2302 | Unknown | 1e+06 cells/kg | — |
| Subject | PRG2302 | Unknown | 2e+06 cells/kg | — |